Carvedilol + Metoprolol succinate + Metoprolol succinate + doxazosin
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Idiopathic Dilated Cardiomyopathy
Conditions
Idiopathic Dilated Cardiomyopathy
Trial Timeline
Sep 1, 2000 → Mar 1, 2009
NCT ID
NCT01798992About Carvedilol + Metoprolol succinate + Metoprolol succinate + doxazosin
Carvedilol + Metoprolol succinate + Metoprolol succinate + doxazosin is a approved stage product being developed by AstraZeneca for Idiopathic Dilated Cardiomyopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT01798992. Target conditions include Idiopathic Dilated Cardiomyopathy.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01798992 | Approved | Completed |
Competing Products
20 competing products in Idiopathic Dilated Cardiomyopathy